Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




UK Government Initiates Competition to Map Rare Cancer Genes

By LabMedica International staff writers
Posted on 17 Dec 2013
A GBP 10 million competition has been established to help biotech companies develop advanced technology to map and analyze genes.

Companies that win the competition will be funded to develop high-tech products to help identify and treat inherited diseases and cancer. More...
Concepts could include new computer code or hardware, or enhancement of existing software and technology. 

The competition will run together with plans to map the DNA code of up to 100,000 UK National Health Service (NHS) patients with cancer and rare diseases by 2017. The products developed as part of the competition will play a part in reaching this goal. Public Health England (London, UK) is also leading work to use whole genome sequencing to treat infectious diseases.

UK Heath Minister Lord Howe said, “Our plans to map 100,000 genomes over the next five years will lead to truly ground-breaking discoveries about how diseases work and how we can treat them more effectively. This competition helps harness the creativity and ingenuity of businesses to help us reach our target. Our investment in pioneering scientific research is good news for patients, for the research sector and for the economy, creating jobs and growth in our world-beating life sciences industry, and helping the UK compete in the global race.”

The competition is part of the Government’s commitment to making the United Kingdom one of the best places to start and grow a business. Application forms and additional details about this competition can be found online (please see Related Links below). The deadline for entries is February 5, 2014. Winning proposals will be announced in March 2014.

The UK Department of Health (DH; London, UK) is funding the competition through the Small Business Research Initiative (SBRI). 

Related Links:

Public Health England
UK Department of Health
Technology Strategy Board

 


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.